#China #Shanghai #biotechnology #Henlius #Serplulimab

Henlius Reports Strong 2025 Annual Results

Henlius, a leading biopharmaceutical company, reported its impressive annual results for 2025, showcasing remarkable growth in revenue and profitability. This marks the company's third consecutive year of achieving profitability since 2023, highlighting its resilience and strategic focus on innovation.

Revenue and Profit Growth

In 2025, Henlius achieved a total revenue of 6.666 billion yuan, signifying a notable year-on-year increase of 16.5%. The company's net profit for the year stood at 0.827 billion yuan, further underscoring its financial stability in a competitive market. With substantial investments in research and development, totaling 2.491 billion yuan—up by 35.4%—Henlius is committed to continuous advancement in innovative solutions.

The company's emphasis on quality growth is evident in its earnings before R&D, which reached 2.342 billion yuan, reflecting an increase of 26.2% year-on-year. This growth trajectory is indicative of Henlius's ongoing commitment to delivering high-quality biopharmaceutical products.

Global Expansion and Product Approval

Henlius has successfully enhanced its global growth momentum, recording total revenues of 5.775 billion yuan from international sales. The successful expansion of its primary products, serplulimab (marketed as Hetronifly® in Europe) and HANQUYOU (trastuzumab, known as HERCESSI™ in the U.S. and Zercepac® in Europe), contributed significantly to this success. Particularly, the company's sales from outside China exceeded 200 million yuan in 2025, doubling from the previous year.

The biopharma innovator has obtained approval for ten products across 60 countries and regions, including four approvals from the FDA and the European Commission. These pivotal approvals have positively impacted over a million patients worldwide with enhanced treatment options.

Notable Achievements in Product Sales

Among its flagship products, serplulimab has continued to demonstrate robust commercial performance, yielding an annual revenue of 1.493 billion yuan, which marks a year-on-year increase of 13.7%. Henlius's oncology product revenues soared to 3.267 billion yuan during the reporting period, showcasing the company's significant impact in cancer treatment.

Furthermore, two dosages of HLX14 (denosumab) were launched successfully in markets such as the U.S., Germany, Spain, and the U.K., generating a substantial revenue of 9.8 million yuan. As Henlius moves forward, its robust pipeline, including key assets like dulpatatug (HLX22, a new anti-HER2 monoclonal antibody) and HLX43 (a PD-L1 ADC), is expected to enter critical clinical phases, paving the way for future innovations.

Commitment to Global Biopharmaceutical Transition

By leveraging its integrated capabilities in research and development, clinical operations, regulatory compliance, manufacturing, and commercialization, Henlius is poised to accelerate its transition to a global biopharmaceutical entity rooted in China. Looking ahead, the company remains dedicated to providing high-quality biological products to patients worldwide, reinforcing its commitment to healthcare advancement and patient outcomes.

In conclusion, the results for 2025 reflect Henlius's strategic focus on sustainable growth and innovation. With its sights set on becoming a formidable player in the global biopharmaceutical landscape, Henlius continues to build on its successes while navigating the complexities of international markets.